National Blood Authority Australia – Annual Report 2008–2009

Our vision, our role, our expenditure

Major achievements in 2008–09

Letter of transmittal

User guide

Part One: Overview

• 1.1 General Manager’s review
• 1.2 National Blood Authority Board Chair’s report
• 1.3 Members of the National Blood Authority Board
• 1.4 Principal Medical Officer’s report
• 1.5 Agency overview
• 1.6 The blood supply chain

Part Two: Our performance

• 2.1 Performance by outcome
• 2.2 Assessment against key strategic directions for 2008–09
  • 2.2.1 Management and implementation of planning, funding and risk management activities in the sector
  • 2.2.2 Supply of blood and blood products
  • 2.2.3 Monitoring and improving the appropriateness and safe use of blood products

Part Three: Future trends and horizon scanning

• 3.1 Introduction
• 3.2 Fresh blood
  • 3.2.1 Transmissible diseases
  • 3.2.2 Testing and manufacturing
  • 3.2.3 Blood management techniques
• 3.3 Plasma products
  • 3.3.1 New plasma-derived products
  • 3.3.2 Substitutes for plasma products
  • 3.3.3 Developments in intravenous immunglobulin
  • 3.3.4 New recombinant products
  • 3.3.5 Plasma market structure
• 3.4 The regulatory environment
• 3.5 Inquiries and legal actions
• 3.6 Conclusion

Part Four: Our management arrangements

• 4.1 Corporate governance
• 4.2 Planning and service delivery
• 4.3 People management
• 4.4 Budget and financial management

Part Five: Our accountability

• 5.1 Purchasing
• 5.2 Asset management
• 5.3 The Commonwealth Disability Strategy
• 5.4 Occupational health and safety
• 5.5 Productivity gains
• 5.6 Ecologically sustainable development
• 5.7 Freedom of information

Part Six: Financial statements

Appendices

• 1. The National Blood Agreement: objectives of governments
• 2. National Blood Authority: Agency resource statement
• 3. Fresh blood components listed on the National Product and Services List 2008–09
• 4. Plasma and recombinant products supplied under contract in 2008–09
• 5. Units of red cells, platelets and IVIg issued per 1000 head of population by state and territory, 2006–07 to 2008–09
• 6. Acronyms

Tables

• 1.1 Government funding to the NBA for the supply of blood and blood-related products
• 1.2 Government funding for the operation of the NBA
• 2.1 NBA’s performance indicators and targets for administered programs
• 2.2 NBA’s performance indicators and targets for departmental programs
• 2.3 Blood and blood-related products purchased, by supplier, in 2007–08 and 2008–09
• 2.4 Actual issues compared to the National Supply Plan and Budget and mid-year review by major product category in 2008–09
• 2.5 ARCBS annual funding 2003–04 to 2008–09
• 2.6 Value of ARCBS annual capital plan funding 2006–07 to 2008–09
• 2.7 Variance between actual supply of fresh blood components against the annual supply estimates
• 2.8 ARCBS Change Program Funding projects 2006–07 to 2008–09
• 2.9 CSL Ltd: annual funding commitments under the Plasma Products Agreements, 2003–04 to 2008–09
• 2.10 CSL Ltd Plasma Products Agreement: key performance indicators, 2008-09
• 2.11 Annual expenditure on imported products (excluding IVIg) by company, 2003–04 to 2008–09
• 2.12 Imported recombinant blood contracts: key performance indicators, by supplier, 2008-09
• 3.1 Notifications of dengue virus infection by year by jurisdiction,1999-2008 and year to date 2009
• 3.2 Potential impacts and time frames of technological developments: a summary
• 4.1 Major risks to the NBA, and remedial action taken, 2008-09
• 4.2 NBA performance indicators for Jurisdictional Blood Committee support, 2008–09
• 4.3 Number of NBA staff at 30 June 2009
• 4.4 Numbers of NBA staff on types of employment agreements
• 4.5 NBA Collective Agreement: 30 June 2009 salary levels
• 4.6 Overall funding and expenditure for the NBA in 2008–09: a summary
• 4.7 Key results in financial performance, 2008-09 and 2007-08
• 4.8 Administered revenue, 2008-09 and 2007-08
• 4.9 Key results of administered expenses, 2008-09 and 2007-08
• 5.1 Expenditure on consultancy services, 2006–07 to 2008–09
• 5.2 Consultancy services of $10 000 or more, 2008–09
• 5.3 Categories of documents held by the NBA

Graphs and Figures

• 1.1 The Australian blood supply chain
• 1.2 Governance structure of the Australian blood sector
• 2.1 Funding allocated by product category, 2008–09
• 2.2 Plasma-derived and overseas product expenditure, 2003–04 to 2008-09
• 2.3 Fresh blood expenditure, 2003-04 to 2008-09
• 2.4 Actual issues performance against the National Supply Plan and Budget and the mid-year review, 2006-07 to 2008-09
• 2.5 Days of red cell supply, by blood type, March to October 2008
• 2.6 Donor attendance in response to a disaster
• 2.7 Product mix of red cells issued by the ARCBS, 2003–04 to 2008–09
• 2.8 Red cells issued per 1000 head of population, 2003–04 to 2008–09
• 2.9 Product mix of platelets issued by the ARCBS, 2003–04 to 2008–09
• 2.10 Platelets issued per 1000 head of population, 2003–04 to 2008–09
• 2.11 Issues of Factor VIII products, 2003–04 to 2008–09
• 2.12 Issues of total Factor VIII per 1000 head of population, 2003–04 to 2008–09
• 2.13 Market share of recombinant Factor VIII issues, 2006–07 to 2008–09
• 2.14 Issues of Factor IX products, 2003–04 to 2008–09
• 2.15 Issues of Factor IX products per 1000 head of population, 2003–04 to 2008–09
• 2.16 Issues of recombinant Factor VIIa, 2003–04 to 2008–09
• 2.17 Issues of FEIBA, 2003–04 to 2008–09
• 2.18 Issues of IVIg products, 2003–04 to 2008–09
• 2.19 Issues of IVIg per 1000 head of population, 2003–04 to 2008–09
• 2.20 Market share for diagnostic reagent products, 2005–06 to 2008–09
• 2.21 Top twelves uses of IVIg, 2004–05 to 2008–09
• 4.1 NBA’s organisational structure
• 4.2 How the NBA manages risk